Tvardi Therapeutics, Inc. 424B3 Filing

Ticker: TVRD · Form: 424B3 · Filed: Apr 1, 2026 · CIK: 0001346830

Tvardi Therapeutics, Inc. 424B3 Filing Summary
FieldDetail
CompanyTvardi Therapeutics, Inc. (TVRD)
Form Type424B3
Filed DateApr 1, 2026
Pages15
Reading Time18 min
Key Dollar Amounts$0.001, $3.18, $207,163,961
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 424B3 filing submitted by Tvardi Therapeutics, Inc. (ticker: TVRD) to the SEC on Apr 1, 2026.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (7 shares of our common stock, par value $0.001 per share (“common stock”)); $3.18 (common stock as reported on Nasdaq was $3.18. This prospectus supplement should be); $207,163,961 (ly completed second fiscal quarter, was $207,163,961. For purposes of this calculation, shar).

How long is this filing?

Tvardi Therapeutics, Inc.'s 424B3 filing is 15 pages with approximately 4,428 words. Estimated reading time is 18 minutes.

Where can I view the full 424B3 filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 4,428 words · 18 min read · ~15 pages · Grade level 14.9 · Accepted 2026-04-01 06:01:20

Key Financial Figures

  • $0.001 — 7 shares of our common stock, par value $0.001 per share (“common stock”)
  • $3.18 — common stock as reported on Nasdaq was $3.18. This prospectus supplement should be
  • $207,163,961 — ly completed second fiscal quarter, was $207,163,961. For purposes of this calculation, shar

Filing Documents

Item 1A. "Risk Factors" of this Annual Report on Form 10-K for a discussion of material factors that

Part I Item 1A. "Risk Factors" of this Annual Report on Form 10-K for a discussion of material factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report on Form 10-K will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K and have filed as exhibits to this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements . 5 Table of Contents RISK FACTORS SUMMARY The following summarizes the principal factors that make an investment in us speculative or risky, all of which are more fully described below. This summary should be read in conjunction with the entire Risk Factors section included elsewhere in this Annual Report on Form 10-K and should not be relied upon as an exhaustive summary of the material risks facing our business. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this Annual Report on Form 10-K and th

View Full Filing

View this 424B3 filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.